Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study

Background and aims: The identification of patients with Hepatitis C Virus (HCV)-positive advanced chronic liver disease (aCLD) successfully treated by Direct Acting Antiviral Agents (DAAs) who really benefit from Hepatocellular Carcinoma (HCC) surveillance programs is still a matter of debate. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciancio, Alessia, Ribaldone, Davide Giuseppe, Spertino, Matteo, Risso, Alessandra, Ferrarotti, Debora, Caviglia, Gian Paolo, Carucci, Patrizia, Gaia, Silvia, Rolle, Emanuela, Sacco, Marco, Saracco, Giorgio Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856119/
https://www.ncbi.nlm.nih.gov/pubmed/36672675
http://dx.doi.org/10.3390/biomedicines11010166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856119/
https://www.ncbi.nlm.nih.gov/pubmed/36672675
http://dx.doi.org/10.3390/biomedicines11010166

Ejemplares similares